Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of atezolizumab plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma and Child-Pugh B (CHALLENGE trial)

Next Previous
Trial Profile

Phase II study of atezolizumab plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma and Child-Pugh B (CHALLENGE trial)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms CHALLENGE

Most Recent Events

  • 04 Jun 2025 New trial record
  • 25 Jan 2025 Status changed from active, no longer recruiting to completed.
  • 19 Nov 2024 According to Results presented at The Liver Meeting 2024: 75th Annual Meeting of the American Association for the Study of Liver Diseases, patients continue to be followed for efficacy endpoints, which will be analyzed after one year from the last patient enrollment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top